Rituxan meets Phase IIb RA endpoint

Updated results from the Phase IIb DANCER trial to treat rheumatoid arthritis (RA) showed that 54% and 55% of patients given 500 or 1,000 mg of Rituxan rituximab from Genentech (DNA) and Biogen Idec (...